NCT05885841View on ClinicalTrials.gov

Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

May 9, 2023

Study Completion Date

May 9, 2023

Conditions
Coronary Artery Disease (CAD)
Interventions
DRUG

XTR004

"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."

Trial Locations (2)

100051

Beijing Hospital, Beijing

100176

Beijing Tongren Hospital, Beijing

All Listed Sponsors
lead

Sinotau Pharmaceutical Group

INDUSTRY